Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Market analysts are pointing to substantial growth potential for Pfizer Inc. following a challenging period for the pharmaceutical giant. While many investor ...

Pfizer (PFE) ended the recent trading session at $25.78, demonstrating a +1.78% change from the preceding day's closing price ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

In the latest trading session, Pfizer (PFE) closed at $23.60, marking a -2.03% move from the previous day. This change lagged the S&P 500's daily loss of 0.5%. Meanwhile, the Dow lost 0.38%, and the ...

Pfizer PFE will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.6 billion and 66 cents ...

While Pfizer Inc's (NYSE:PFE) revenue trends remained uneven in the third quarter, the company exhibited "continued cost discipline," according to Goldman Sachs. The Pfizer Analyst: Analyst Asad ...

Pfizer Inc. crushed Q2 estimates with a 36% EPS beat, proving its operational turnaround is gaining momentum despite negative market sentiment and recent stock underperformance. Aggressive ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

After its best day in nearly four years Tuesday, Pfizer stock gave an encore performance. Shares of the drugmaker closed up 6.8% as investors digested Tuesday's news that Pfizer would get a three-year ...